MarketBeat
11 Nov 2026, 02:16 UTC · 14h ago
What Lumexa Imaging (LMRI) Said on Its Q3 Earnings Call
Impact · against what's priced in
Lumexa Imaging's stock is likely to see a positive reaction due to significant improvements in its balance sheet and an upgraded earnings outlook. While a minor Medicare reimbursement headwind exists for 2027, the immediate impact of reduced leverage and higher free cash flow targets provides a catalyst.
- LMRI+0.60
No priced-in read yet
- In context
The company raised its 2026 adjusted EPS forecast to $0.86-$0.90 and substantially reduced net leverage from 5.6x to 3.5x. Additionally, the new guidance that free cash flow will be at least 30% of adjusted EBITDA suggests stronger capital generation than previously expected.
Read from the article alone
